FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894784273> ?p ?o ?g. }

• W2894784273 endingPage "746A" @default.
• W2894784273 startingPage "745A" @default.
• W2894784273 abstract "SESSION TITLE: Obstructive Lung Diseases 1 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2018 01:00 PM - 02:00 PM PURPOSE: Inhalers should be easy to operate correctly to ensure effective delivery of inhaled medications. Two multi center, single-arm, placebo, Ph IV studies were conducted to evaluate ease and correct use of the ELLIPTA inhaler in adults with asthma (GSK study 201594/NCT02586506) or COPD (GSK study 201071/NCT02586493). METHODS: Asthma & COPD pts receiving maintenance therapy, but no prior/ongoing use of an ELLIPTA inhaler (w/i 6 months for COPD), were eligible. Pts demonstrating correct inhaler use within 3 attempts were instructed to take once-daily inhalations from a placebo ELLIPTA inhaler for 28±2 days, while continuing usual therapy. Easy to use was defined as a rating of ‘easy’ or ‘very easy’ on a 4-point scale (very easy, easy, difficult, very difficult) and was only assessed for pts who demonstrated correct use of the study inhaler on the 1st attempt as assessed by the inhaler-trained HCP. At study end, pts were randomized 1:1 to complete 1 of 2 versions of an ease-of-use questionnaire (differing response order) and were re-assessed for correct use. RESULTS: 259 asthma and 278 COPD pts were enrolled; 250 asthma and 267 COPD pts were included in the modified intent to treat (mITT) population for analyses*†. Overall, 96% of asthma pts and 93% of COPD pts rated the inhaler as ‘easy’ or ’very easy’ to use and demonstrated correct inhaler use. A post-hoc analysis by age group was conducted for both studies. In the asthma study, 94% of pts in the 18-44yrs group (n=98) reported ELLIPTA as ‘easy’ or ‘very easy’ to use and demonstrated correct inhaler use; 97% of the pts in the 45-64yrs group (n=116) and 97% of pts in the ≥65yrs (n=36) group also reported the same. Similarly, in the COPD study, 95% of pts in the 40-64yrs group (n=129) reported ELLIPTA as ‘easy’ or ‘very easy’ to use; 90% in the 65-74yrs group (n=105) and 100% in the ≥75yrs group (n=33) also reported the same. AE rates were 12% and 15% in the asthma and COPD studies, respectively; the most frequent AE was headache (3% in both). [*mITT population=all pts who were screened (Visit 1), who received ≥1 dose of placebo study treatment, and who were randomized to receive the ease-of-use questionnaire at study end (Visit 2). In both studies, the mITT population was used for analysis of the pre-specified primary and secondary endpoints. †One pt in the COPD mITT population was randomized in error and did not complete the ease-of-use questionnaire.] CONCLUSIONS: The ELLIPTA was operated correctly and rated ‘easy’ or ‘very easy’ to use by the majority of pts with asthma and COPD. Correct use and ease of use was similar across all age groups, including those ≥65 years in both asthma and COPD as well as those ≥75 years for COPD. CLINICAL IMPLICATIONS: Inhaler ease of use is important when selecting asthma and COPD treatments and may improve treatment compliance. Regardless of age, ≥90% of pts with asthma or COPD rated ELLIPTA as easy to use. Funded by GSK DISCLOSURES: Employee relationship with GlaxoSmithKline Pharmaceuticals Please note: >$100000 Added 02/28/2018 by Lee Baylis, source=Web Response, value=Salary Owner of shares relationship with GlaxoSmithKline Please note: >$100000 Added 02/28/2018 by Kathryn Collison, source=Web Response, value=Shares Removed 02/28/2018 by Kathryn Collison, source=Web Response Employee relationship with GlaxoSmithKline Please note: >$100000 Added 02/28/2018 by Kathryn Collison, source=Web Response, value=Salary Owner of shares relationship with GlaxoSmitjKline Please note: $20001 - $100000 Added 02/28/2018 by Kathryn Collison, source=Web Response, value=Share Employee relationship with GSK Please note: >$100000 Added 02/28/2018 by Renu Jain, source=Web Response, value=Salary Employee relationship with GlaxoSmithKline Please note: >$100000 Added 02/28/2018 by David Mannino, source=Web Response, value=Salary Employee relationship with GlaxoSmithKline Please note: $20001 - $100000 Added 02/28/2018 by David Mannino, source=Web Response, value=Ownership interest No relevant relationships by Pinal Patel, source=Web Response Employee relationship with GlaxoSmithKline Please note: >$100000 Added 02/06/2018 by Laura Sutton, source=Web Response, value=Salary" @default.
• W2894784273 created "2018-10-12" @default.
• W2894784273 creator A5004313879 @default.
• W2894784273 creator A5016653569 @default.
• W2894784273 creator A5029632697 @default.
• W2894784273 creator A5044084700 @default.
• W2894784273 creator A5075758556 @default.
• W2894784273 creator A5085440448 @default.
• W2894784273 date "2018-10-01" @default.
• W2894784273 modified "2023-09-25" @default.
• W2894784273 title "EASE AND CORRECT USE OF ELLIPTA BY AGE IN PATIENTS WITH ASTHMA AND COPD" @default.
• W2894784273 doi "https://doi.org/10.1016/j.chest.2018.08.673" @default.
• W2894784273 hasPublicationYear "2018" @default.
• W2894784273 type Work @default.
• W2894784273 sameAs 2894784273 @default.
• W2894784273 citedByCount "3" @default.
• W2894784273 countsByYear W28947842732021 @default.
• W2894784273 countsByYear W28947842732022 @default.
• W2894784273 crossrefType "journal-article" @default.
• W2894784273 hasAuthorship W2894784273A5004313879 @default.
• W2894784273 hasAuthorship W2894784273A5016653569 @default.
• W2894784273 hasAuthorship W2894784273A5029632697 @default.
• W2894784273 hasAuthorship W2894784273A5044084700 @default.
• W2894784273 hasAuthorship W2894784273A5075758556 @default.
• W2894784273 hasAuthorship W2894784273A5085440448 @default.
• W2894784273 hasConcept C126322002 @default.
• W2894784273 hasConcept C142724271 @default.
• W2894784273 hasConcept C1862650 @default.
• W2894784273 hasConcept C204787440 @default.
• W2894784273 hasConcept C27081682 @default.
• W2894784273 hasConcept C2776042228 @default.
• W2894784273 hasConcept C2776780178 @default.
• W2894784273 hasConcept C2777419714 @default.
• W2894784273 hasConcept C2780261241 @default.
• W2894784273 hasConcept C2908647359 @default.
• W2894784273 hasConcept C71924100 @default.
• W2894784273 hasConcept C99454951 @default.
• W2894784273 hasConceptScore W2894784273C126322002 @default.
• W2894784273 hasConceptScore W2894784273C142724271 @default.
• W2894784273 hasConceptScore W2894784273C1862650 @default.
• W2894784273 hasConceptScore W2894784273C204787440 @default.
• W2894784273 hasConceptScore W2894784273C27081682 @default.
• W2894784273 hasConceptScore W2894784273C2776042228 @default.
• W2894784273 hasConceptScore W2894784273C2776780178 @default.
• W2894784273 hasConceptScore W2894784273C2777419714 @default.
• W2894784273 hasConceptScore W2894784273C2780261241 @default.
• W2894784273 hasConceptScore W2894784273C2908647359 @default.
• W2894784273 hasConceptScore W2894784273C71924100 @default.
• W2894784273 hasConceptScore W2894784273C99454951 @default.
• W2894784273 hasIssue "4" @default.
• W2894784273 hasLocation W28947842731 @default.
• W2894784273 hasOpenAccess W2894784273 @default.
• W2894784273 hasPrimaryLocation W28947842731 @default.
• W2894784273 hasRelatedWork W1985297785 @default.
• W2894784273 hasRelatedWork W2109586110 @default.
• W2894784273 hasRelatedWork W2153441442 @default.
• W2894784273 hasRelatedWork W2790147388 @default.
• W2894784273 hasRelatedWork W2904406609 @default.
• W2894784273 hasRelatedWork W2906043870 @default.
• W2894784273 hasRelatedWork W4288721600 @default.
• W2894784273 hasRelatedWork W4315780469 @default.
• W2894784273 hasRelatedWork W2473810395 @default.
• W2894784273 hasRelatedWork W3087902455 @default.
• W2894784273 hasVolume "154" @default.
• W2894784273 isParatext "false" @default.
• W2894784273 isRetracted "false" @default.
• W2894784273 magId "2894784273" @default.
• W2894784273 workType "article" @default.